TECHNOPHAGE and SIMM, SHANGHAI INSTITUTE OF MATERIA MEDICA, a state-owned Institute administered and existing under the laws of the People’s Republic of China, have signed today a collaboration agreement for the joint development of a new pharmaceutical drug, leveraging the know-how and scientific complementarities of both entities in order to exploit new opportunities in the global pharmaceutical market.